---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-172678"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T19:14:00.651274+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Taysha regains Nasdaq independence compliance; Manning resigns, Stalfort appointed

## Summary
- Paul Manning resigned from board effective June 20, 2023 to enable compliance with Nasdaq Rule 5605(b)(1); remains as non-voting observer.
- Sean Stalfort appointed as independent Class I director, chair of Nominating/Governance Committee, and member of Compensation Committee.
- Stalfort granted option for 43,800 shares at closing price, vesting over 36 months; annual retainer $35k plus committee fees.
- Majority of board now independent; company has regained compliance with Nasdaq listing requirements.

## SEC filing metadata
- accession: 0001193125-23-172678
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/0001193125-23-172678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/d321956d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-172678
- JSON: https://secwatch.observer/filing/0001193125-23-172678.json
- Plain text: https://secwatch.observer/filing/0001193125-23-172678.txt

## Key facts
- Executive change
  Sean Stalfort was appointed as director at Taysha Gene Therapies, Inc..
  - Action: appointed
  - Role: director
  source text: on June 21, 2023, the Board appointed Sean Stalfort to serve as a director of the Company, effective immediately following Mr. Manning’s resignation
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/0001193125-23-172678-index.htm
- Executive change
  Paul B. Manning resigned as director at Taysha Gene Therapies, Inc..
  - Action: resigned
  - Role: director
  source text: on June 20, 2023, Paul B. Manning provided notice to the Board of his decision to resign from the Board and all committees thereof
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/0001193125-23-172678-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.